Managed Care Operations Memorandum
General Operations
MCOPS Memo # 08/2018-014

Date: August 15, 2018

Subject: Technology Assessment Group (TAG) Coverage Decisions

To: Physical Health HealthChoices Managed Care Organizations (PH-MCOs) – Statewide

From: Laurie Rock, Director, Bureau of Managed Care Operations, Office of Medical Assistance Programs

---

Purpose:

To provide PH-MCOs coverage updates on new technologies as discussed in regular TAG meetings.

Background:

The TAG workgroup meets quarterly on the first (1st) Wednesday of February, May, August and November to discuss issues revolving around new technologies and technologies or services that were previously considered to be a program exception. During this meeting, decisions are made as to whether or not certain technologies will be covered and how they will be covered. TAG's decisions are as follows:

- **Option #1:** Approved- Will be added to the Fee Schedule
- **Option #2:** Approved as Medically Effective- will require Program Exception
- **Option #3:** Approved with (or denied due to) Limited/Minimal Evidence of Effectiveness- will require Program Exception
- **Option #4:** Denied- Experimental/Investigational

Discussion:

Below are the updated list of codes/descriptions discussed at the August 2018, TAG Meeting and the decisions that were made:

HCPCS/CPT Code	Description	Decision
81514	Polaris – Prostate Cancer Test. This test is an in vitro	Option # 4

	prognostic assay that measures gene expression in tumor samples isolated from prostate cancer patients with clinically localized prostate cancer.	
0398T 0071T 0072T	Magnetic Resonance (MR) Guided Focused Ultrasound (MRgFUS) for Metastatic Bone Disease, Uterine Fibroids and Essential Tremors. The magnetic resonance-guided ultrasound technology uses MRI imaging to guide high powered, focused ultrasound to a very small point. At that point, molecules create intense local heat by being vibrated extremely quickly. The heat then can "cook" tissue and destroy it. This technology allows the clinician to target a specific spot and only the targeted tissue is affected.	Option # 4
81599	EndoPredict. The 12-gene molecular score is combined with clinicopathologic features of breast cancer (tumor size and lymph node status) to produce the EndoPredict score. This score is reported as low-or high-risk and includes a personalized risk of 10-year distant reoccurrence (DR). This score is used to predict whether chemotherapy is a benefit for women with ER positive, HER2 negative early stage breast cancer and their possibility within the next 10- years of reoccurrence.	Option # 4

This memo is not intended to replace any existing Prior Authorization Review Processes currently being utilized; it is for informational/internal purposes only.

Next Steps:

N/A

Obsolete:

N/A

Attachment:

N/A